Prolonged infusion of bivalirudin after elective percutaneous coronary intervention protects against procedural myocardial injury (a COBER study)—a randomized trial

• Published in: Scientific reports Vol. 13; no. 1; pp. 6667 - 9
• Main Authors: Wu, Zhiming, Meng, Peina, Guo, Yajie, You, Wei, Wu, Xiangqi, Ye, Fei
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.04.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4019; 692/4019/2776; Angioplasty; Anticoagulants; Bleeding; Heart; Hemorrhage - etiology; Hirudins; Humanities and Social Sciences; Humans; multidisciplinary; Myocardial Infarction - etiology; Peptide Fragments - adverse effects; Percutaneous Coronary Intervention - adverse effects; Science; Science (multidisciplinary); Treatment Outcome; Troponin I
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-34008-y

Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included ( n  = 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%], P  = 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%], P  = 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) ( P  = 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%], P  = 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding. ClinicalTrials.gov.Number: NCT04120961, 09/10/2019.